DBV Technologies S.A. - 8-K Filing

DBV submitted a Biologics License Application to the FDA for VIASKIN® Peanut Patch in children aged 4–7 years and requested Priority Review. (Items: 8.01 Other Events On September 29, 2026, DBV Technologies S, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $DBVT

Read the full article at SEC EDGAR

More Regulatory news